Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leukovorin.

Abstract	Implantation of 2-hydroxyethylmethacrylate microporous carrier with sorbed methotrexate (Hema-Hex-MTX) proved more toxic on C3H strain mice with a solid Gardner lymphosarcoma than on tumor-free mice of the same strain. If, during the first week of the experimental disease, the Hema-Hex-MTX implantation was followed by administration of leukovorin in course of next 24 hours the toxicity of MTX was abolished and the treated mice survived significantly longer than control animals.
Authors	K Motycka, K Slavík, A Balcarbová, R Cihar, P Spacek, M Kubín
Journal	Neoplasma (Neoplasma) Vol. 25 Issue 2 Pg. 217-25 ( 1978) ISSN: 0028-2685 [Print] Slovakia
PMID	306074 (Publication Type: Journal Article)
Chemical References	Drug Implants Gels Methacrylates Leucovorin Methotrexate
Topics	Animals Drug Implants Drug Therapy, Combination Female Gels Leucovorin (therapeutic use) Lymphoma, Non-Hodgkin (drug therapy) Male Methacrylates Methotrexate (administration & dosage, therapeutic use, toxicity) Mice Mice, Inbred C3H Sarcoma, Experimental (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!